Enhancing anti-viral neutralization response to immunization with HIV-1 envelope glycoprotein immunogens.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
24 Nov 2023
24 Nov 2023
Historique:
received:
02
04
2023
accepted:
06
11
2023
medline:
24
11
2023
pubmed:
24
11
2023
entrez:
23
11
2023
Statut:
epublish
Résumé
An effective human immunodeficiency virus type I (HIV-1) vaccine that robustly elicits broadly neutralizing antibodies (bnAbs) against HIV-1 envelope glycoproteins (Envs) to block viral entry is still not available. Thus, identifying triggers for elicitation of different types of anti-HIV-1 Env antibodies by vaccination could provide further guidance for immunogen design and vaccine development. Here, we studied the immune response to HIV-1 Env immunogens in rabbits. We show that sequential immunizations with conformation-specific Env immunogens can elicit low titer but broad neutralization responses against heterologous, neutralization-resistant (tier 2/3) transmitted/founder (T/F) HIV-1 strains. More importantly, an mRNA vaccine candidate that could mediate the presentation of a cytoplasmic tail-deleted (ΔCT) HIV-1
Identifiants
pubmed: 37996435
doi: 10.1038/s41541-023-00774-z
pii: 10.1038/s41541-023-00774-z
pmc: PMC10667240
doi:
Types de publication
Journal Article
Langues
eng
Pagination
181Subventions
Organisme : NIAID NIH HHS
ID : T32 AI055433
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Cell Rep. 2020 Jun 9;31(10):107749
pubmed: 32521274
ACS Infect Dis. 2023 Jan 13;9(1):5-8
pubmed: 36512322
STAR Protoc. 2020 Dec 09;1(3):100209
pubmed: 33377103
Nat Rev Mater. 2021;6(12):1078-1094
pubmed: 34394960
Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19769-74
pubmed: 23129652
Nat Med. 2022 Sep;28(9):1924-1932
pubmed: 35995954
N Engl J Med. 2012 Apr 5;366(14):1275-86
pubmed: 22475592
Science. 2022 Dec 2;378(6623):eadd6502
pubmed: 36454825
Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6626-33
pubmed: 23542380
Nature. 2008 Sep 4;455(7209):109-13
pubmed: 18668044
Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7
pubmed: 18490657
Nature. 2016 May 5;533(7601):105-109
pubmed: 27120156
J Immunol. 2010 Dec 15;185(12):7623-32
pubmed: 21076072
Nat Commun. 2017 Oct 19;8(1):1049
pubmed: 29051495
Nature. 2016 Jul 7;535(7610):136-9
pubmed: 27309817
Nat Chem Biol. 2014 Oct;10(10):845-52
pubmed: 25174000
Angew Chem Int Ed Engl. 2021 Jan 4;60(1):321-330
pubmed: 32886840
PLoS One. 2011;6(11):e26731
pubmed: 22069466
J Med Chem. 2008 Sep 25;51(18):5702-13
pubmed: 18800765
Gene. 1995 Nov 20;165(2):233-8
pubmed: 8522182
Nat Med. 2021 Dec;27(12):2234-2245
pubmed: 34887575
Mol Ther Nucleic Acids. 2019 Apr 15;15:26-35
pubmed: 30933724
ACS Infect Dis. 2021 Jun 11;7(6):1558-1568
pubmed: 34006087
Sci Rep. 2016 Jan 19;6:19234
pubmed: 26781591
Mol Ther. 2019 Apr 10;27(4):824-836
pubmed: 30638957
Nature. 2013 Nov 14;503(7475):224-8
pubmed: 24172905
Cell Rep. 2017 Aug 22;20(8):1805-1817
pubmed: 28834745
J Virol. 2014 May;88(9):5014-28
pubmed: 24554659
STAR Protoc. 2020 Oct 14;1(3):100133
pubmed: 33377027
Eur J Med Chem. 2011 Feb;46(2):447-67
pubmed: 21159409
mBio. 2016 Oct 25;7(5):
pubmed: 27795397
AIDS Res Hum Retroviruses. 2018 Sep;34(9):794-803
pubmed: 29905080
ACS Nano. 2018 Sep 25;12(9):8855-8866
pubmed: 30028591
N Engl J Med. 2021 Mar 18;384(11):1003-1014
pubmed: 33730454
Nat Med. 2018 Nov;24(11):1701-1707
pubmed: 30258217
Science. 2015 Jul 17;349(6245):320-4
pubmed: 26138104
Chimia (Aarau). 2019 May 29;73(6):391-394
pubmed: 31118121
Cell. 2015 Sep 10;162(6):1379-90
pubmed: 26359989
Science. 2014 Nov 7;346(6210):759-63
pubmed: 25298114
J Virol. 2013 Jun;87(12):7191-6
pubmed: 23596305